# Commercial PA Criteria

***Effective: June 3, 2020***

***Prior Authorization:*** Xcopri

***Products Affected:*** Xcopri (cenobamate) oral tablets

***Medication Description:*** Xcopri is approved for the treatment of partial onset seizures in adult patients. The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown. Cenobamate reduces repetitive neuronal firing by inhibiting voltage-gated sodium currents and is a positive allosteric modulator of the gamma-aminobutyric acid (GABA-A) ion channel.

***Covered Uses:*** Partial-onset seizure

***Exclusion Criteria:*** Familial Short QT syndrome

***Required Medical Information:***

1) Diagnosis
2) Previous therapies tried and failed

***Age Restrictions:*** 18 years of age and older

***Prescriber Restrictions:*** Xcopri is being prescribed by, or in consultation with, a neurologist

***Coverage Duration:*** 12 months

***Other Criteria:***

A. Patient must have a diagnosis of partial-onset seizures; **AND**
B. The patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, levetiracetam, carbamazepine, lamotrigine, topiramate, phenytoin, or oxcarbazepine)

***References:***


1. Xcopri [product insert]. SK Biopharmaceuticals. Paramus, NJ. November 2019.
2. Xcopri. Lexicomp Online [Internet database], Hudson, Ohio: Wolters Kluwer Health, Inc; May 20, 2020.


***Policy Revision history***

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|---|---|---|---|---|
| 1 | New Policy | New Policy | All | 06/03/2020 |
| 2 | Annual Review | No criteria changes | No criteria changes | 5/14/2024 |




Confidential Information

This document is confidential and proprietary to ConnectiCare, Inc. Unauthorized use and distribution are prohibited.